Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric drug maker Pernix Therapeutics nets $19.7mm in RDO

Executive Summary

Pernix Therapeutics Holdings Inc. (branded and generic pediatric products for allergy, upper respiratory conditions, infectious disease, and dermatological disorders) netted $19.7mm in a registered direct offering of 3mm shares at $7 (a 22% discount). Aisling Capital and OrbiMed Advisors were the lead investors. Pernix’s management and board also sold 1mm shares in the RDO (but the company will not realize any of those proceeds).
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Biotech
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register